Saturday, December 12, 2015

The Use of Reimbursement Data for Timely Monitoring of Vaccination Coverage: The Example of Human Papillomavirus Vaccine Following Public Concerns About Vaccine Safety

Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage.

We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97 th health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15 th , 16 th and 17 th birthday.

The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014.

HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures.

Below:  Vaccination coverage with one dose of HPV vaccine at 15 th birthday and three doses at 16 th birthday, by quarter periods, January 2010–June 2014

Below:  Cumulative vaccination coverage for 3 doses of HPV vaccine according to age and half year of birth. France

Full article at:

By:   Laure Fonteneau12, Marine Ragot1, Isabelle Parent du Châtelet1, Jean-Paul Guthmann1and Daniel Lévy-Bruhl1*
1Institut de Veille Sanitaire (InVS), Saint-Maurice, France
2European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden

No comments:

Post a Comment